Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 14, 2014

View Archived Issues

Sanofi reports progress across key programs in fourth quarter 2013

Revive Therapeutics reports interim data from phase IIa study of REV-001

Canadian researchers patent new immunoglobulin constructs

New vaccine company Abivax created

Pierre Fabre obtains worldwide rights to immune checkpoint modulator from Aurigene

Development of a dual serotonin receptor antagonist for the treatment of patients with dementia

FDA grants full approval to Synribo for injection

X-Chem licenses epigenetic program to Bayer Pharma

Aerpio Therapeutics begins phase II study of AKB-9778 in diabetic macular edema

Merck & Co. presents new ROMK blockers

Sphaera Pharma designs new signal transduction inhibitors for cancer

Bristol-Myers Squibb prepares novel P2Y1 receptor antagonists for thrombosis

Agenus aims to develop cancer immunotherapy program with acquisition of 4-Antibody

Bionomics prepares new nicotinic acetylcholine receptor modulators

Scientists at Bristol-Myers Squibb patent new AAK1 inhibitors for pain and other disorders

Preliminary phase II results presented for pazopanib/paclitaxel combination in urothelial carcinoma

Decreased GATA1 mRNA expression associated with poor clinical prognosis in ccRCC

Lilly describes nonsteroidal glucocorticoid antagonist that minimizes treatment-related weight gain

Otsuka Pharmaceutical recaps highlights of third quarter of fiscal 2013

Isis Pharmaceuticals provides update on trials of ISIS-SMNRx in spinal muscular atrophy

Ampio reports preliminary findings from biochemical analysis from SPRING study

Alexion, Prothelia and University of Nevada enter agreements for laminin-111

SwissMedic approves Actelion's Opsumit for pulmonary arterial hypertension

AVEO and Astellas to end worldwide tivozanib collaboration

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 21, 2026
Psychedelic space expanding on Trump’s EO
BioWorld
Timothy Leary is dead, but he could be on the outside looking in with a smile on his face as U.S. President Donald Trump’s latest executive order (EO) fuels a...
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...